KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Gains from Investment Securities (2017 - 2025)

Historic Gains from Investment Securities for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $129000.0.

  • Amneal Pharmaceuticals' Gains from Investment Securities rose 11118.82% to $129000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $28.1 million, marking a year-over-year increase of 292701.83%. This contributed to the annual value of $15.2 million for FY2024, which is 20498.72% up from last year.
  • As of Q3 2025, Amneal Pharmaceuticals' Gains from Investment Securities stood at $129000.0, which was up 11118.82% from $189000.0 recorded in Q2 2025.
  • Amneal Pharmaceuticals' 5-year Gains from Investment Securities high stood at $22.6 million for Q4 2022, and its period low was -$27.1 million during Q4 2021.
  • For the 5-year period, Amneal Pharmaceuticals' Gains from Investment Securities averaged around $802777.8, with its median value being $244500.0 (2021).
  • Per our database at Business Quant, Amneal Pharmaceuticals' Gains from Investment Securities crashed by 62189.47% in 2023 and then soared by 50423.39% in 2024.
  • Amneal Pharmaceuticals' Gains from Investment Securities (Quarter) stood at -$27.1 million in 2021, then soared by 183.24% to $22.6 million in 2022, then plummeted by 135.97% to -$8.1 million in 2023, then soared by 175.85% to $6.2 million in 2024, then plummeted by 97.91% to $129000.0 in 2025.
  • Its Gains from Investment Securities stands at $129000.0 for Q3 2025, versus $189000.0 for Q2 2025 and $21.6 million for Q1 2025.